N Flamand1, S Picard, L Lemieux, M Pouliot, S G Bourgoin, P Borgeat. 1. Département d'anatomic et de physiologie, Centre de Recherche en Rhumatologie et Immunologie, Centre de recherche du CHUQ (CHUL), Faculté de Médecine, Université Laval, Québec, Canada.
Abstract
BACKGROUND AND PURPOSE: The biosynthesis of leukotrienes (LT) and platelet-activating factor (PAF) involves the release of their respective precursors, arachidonic acid (AA) and lyso-PAF by the group IVA PLA2 (cPLA2alpha). This paper aims at characterizing the inhibitory properties of the cPLA2alpha inhibitor pyrrophenone on eicosanoids and PAF in human neutrophils (PMN). EXPERIMENTAL APPROACH: Freshly isolated human PMN were activated with physiological and pharmacological agents (fMLP, PAF, exogenous AA, A23187 and thapsigargin) in presence and absence of the cPLA2alpha inhibitor pyrrophenone and biosynthesis of LT, PAF, and PGE2 was measured. KEY RESULTS: Pyrrophenone potently inhibited LT, PGE2 and PAF biosynthesis in PMN with IC50s in the range of 1-20 nM. These inhibitory effects of pyrrophenone were specific (the consequence of substrate deprivation), as shown by the reversal of inhibition by exogenous AA and lyso-PAF. Comparative assessment of pyrrophenone, methyl-arachidonoyl-fluoro-phosphonate (MAFP) and arachidonoyl-trifluoromethylketone (AACOCF3) demonstrated that pyrrophenone was more specific and 100-fold more potent than MAFP and AACOCF3 for the inhibition of LT biosynthesis in A23187-activated PMN. The inhibitory effect of pyrrophenone on LT biosynthesis was reversible as LT biosynthesis was recovered when pyrrophenone-treated PMN were washed with autologous plasma. No alteration of phospholipase D (PLD) activity in fMLP-activated PMN was observed with up to 10 microM pyrrophenone, suggesting that the cPLA2alpha inhibitor does not directly inhibit PLD. CONCLUSIONS AND IMPLICATIONS: Pyrrophenone is a more potent and specific cPLA2alpha inhibitor than MAFP and AACOCF3 and represents an excellent pharmacological tool to investigate the biosynthesis and the biological roles of eicosanoids and PAF.
BACKGROUND AND PURPOSE: The biosynthesis of leukotrienes (LT) and platelet-activating factor (PAF) involves the release of their respective precursors, arachidonic acid (AA) and lyso-PAF by the group IVAPLA2 (cPLA2alpha). This paper aims at characterizing the inhibitory properties of the cPLA2alpha inhibitor pyrrophenone on eicosanoids and PAF in human neutrophils (PMN). EXPERIMENTAL APPROACH: Freshly isolated humanPMN were activated with physiological and pharmacological agents (fMLP, PAF, exogenous AA, A23187 and thapsigargin) in presence and absence of the cPLA2alpha inhibitor pyrrophenone and biosynthesis of LT, PAF, and PGE2 was measured. KEY RESULTS:Pyrrophenone potently inhibited LT, PGE2 and PAF biosynthesis in PMN with IC50s in the range of 1-20 nM. These inhibitory effects of pyrrophenone were specific (the consequence of substrate deprivation), as shown by the reversal of inhibition by exogenous AA and lyso-PAF. Comparative assessment of pyrrophenone, methyl-arachidonoyl-fluoro-phosphonate (MAFP) and arachidonoyl-trifluoromethylketone (AACOCF3) demonstrated that pyrrophenone was more specific and 100-fold more potent than MAFP and AACOCF3 for the inhibition of LT biosynthesis in A23187-activated PMN. The inhibitory effect of pyrrophenone on LT biosynthesis was reversible as LT biosynthesis was recovered when pyrrophenone-treated PMN were washed with autologous plasma. No alteration of phospholipase D (PLD) activity in fMLP-activated PMN was observed with up to 10 microM pyrrophenone, suggesting that the cPLA2alpha inhibitor does not directly inhibit PLD. CONCLUSIONS AND IMPLICATIONS: Pyrrophenone is a more potent and specific cPLA2alpha inhibitor than MAFP and AACOCF3 and represents an excellent pharmacological tool to investigate the biosynthesis and the biological roles of eicosanoids and PAF.
Authors: Norbert Degousee; Farideh Ghomashchi; Eva Stefanski; Alan Singer; Brian P Smart; Niels Borregaard; Reinhardt Reithmeier; Thomas F Lindsay; Cornelia Lichtenberger; Walter Reinisch; Gerard Lambeau; Jonathan Arm; Jay Tischfield; Michael H Gelb; Barry B Rubin Journal: J Biol Chem Date: 2001-12-06 Impact factor: 5.157
Authors: Sonya Grenier; Nicolas Flamand; Julie Pelletier; Paul H Naccache; Pierre Borgeat; Sylvain G Bourgoin Journal: J Leukoc Biol Date: 2003-04 Impact factor: 4.962
Authors: Pamela J Kell; Michael H Creer; Kimberley N Crown; Karin Wirsig; Jane McHowat Journal: J Pharmacol Exp Ther Date: 2003-10-14 Impact factor: 4.030
Authors: Paul C Norris; David Gosselin; Donna Reichart; Christopher K Glass; Edward A Dennis Journal: Proc Natl Acad Sci U S A Date: 2014-08-19 Impact factor: 11.205
Authors: Bogeon Yun; HeeJung Lee; Heather Ewing; Michael H Gelb; Christina C Leslie Journal: Biochem Biophys Res Commun Date: 2016-09-09 Impact factor: 3.575
Authors: John E Burke; Arneh Babakhani; Alemayehu A Gorfe; George Kokotos; Sheng Li; Virgil L Woods; J Andrew McCammon; Edward A Dennis Journal: J Am Chem Soc Date: 2009-06-17 Impact factor: 15.419
Authors: Luc H Boudreau; Jacques Maillet; Luc M LeBlanc; Jacques Jean-François; Mohamed Touaibia; Nicolas Flamand; Marc E Surette Journal: PLoS One Date: 2012-02-09 Impact factor: 3.240
Authors: Hongyu Wu; Mikhail Bogdanov; Yujin Zhang; Kaiqi Sun; Shushan Zhao; Anren Song; Renna Luo; Nicholas F Parchim; Hong Liu; Aji Huang; Morayo G Adebiyi; Jianping Jin; Danny C Alexander; Michael V Milburn; Modupe Idowu; Harinder S Juneja; Rodney E Kellems; William Dowhan; Yang Xia Journal: Sci Rep Date: 2016-07-20 Impact factor: 4.379